Sugi Predict

Sugi Predict / Compounds / SCHEMBL16189355

SCHEMBL16189355

SCHEMBL16189355

Cc1cccc(-c2cccc(-c3nc(-c4ccccc4)nc(-c4cccc(-c5cccc(C)n5)c4)n3)c2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 1/20 0.52
▸ CCR8 P51685 1/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ CYP2A6 P11509 1/20 0.50
▸ LMNA P02545 3/20 0.47
▸ MEN1 O00255 6/20 0.47
▸ KMT2A Q03164 6/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ TGFBR1 P36897 1/20 0.46
▸ MAPT P10636 4/20 0.46
▸ HPGD P15428 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ GLA P06280 1/20 0.46
▸ GRM5 P41594 1/20 0.43
▸ ABCG2 Q9UNQ0 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16189074 1.00 CCR1 (0.52) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL16189409 0.97 L3MBTL1 (0.48) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL17932800 0.97 L3MBTL1 (0.48) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL16189352 0.95 CCR1 (0.50) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL16189316 0.94 CCR1 (0.58) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL19543719 0.93 CCR1 (0.48) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL17932783 0.92 MEN1 (0.49) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL16189265 0.92 MEN1 (0.49) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL19009474 0.91 L3MBTL1 (0.50) CCR1CCR8L3MBTL1CYP2A6LMNA
SCHEMBL16189377 0.89 CCR1 (0.52) CCR1CCR8L3MBTL1CYP2A6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 — — US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 — — US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 — — US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 — — US disclosed
WO-2014171541-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE ELEMENT AND APPLICATION THEREFOR 東ソー株式会社 (JP) 2014-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 CCR1 4739/4885CCR8 3723/4885L3MBTL1 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.